Abstract: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.

Abstract: Provided is a low-cost, highly active, environmentally friendly living radical polymerization catalyst which does not require a radical initiator. An organic compound having an oxidation-reduction capability is used as a catalyst. Even if a radical initiator is not used, a monomer can be subjected to a radical polymerization to obtain a polymer having narrow molecular weight distribution. The cost of the living radical polymerization can be remarkably reduced. It is made possible to prevent adverse effects of using a radical initiator. The present invention is significantly more environmentally friendly and economically excellent than conventional living radical polymerization methods, due to advantages of the catalyst such as low toxicity of the catalyst, low amount of the catalyst necessary, high solubility of the catalyst, mild reaction conditions, and no coloration/no odor (which do not require a post-treatment for a molded article), etc.

Abstract: A novel phosphine compound capable of forming a metal complex useful as a catalyst for various asymmetric synthesis reactions, a production method thereof, and a metal complex comprising the aforementioned compound as a ligand.

Abstract: The present invention relates to a process for preparing an enantioenriched phosphorus-stereogenic, tertiary phosphine. Secondary phosphines are contacted with an alkyl halide and base in the presence of a chiral metal catalyst thereby producing the enantioenriched phosphorus-stereogenic, tertiary phosphine for subsequent use in homogeneous catalysis reactions.

Abstract: Provided is an acenaphtho[1,2-k]benzo[e]acephenanthrene derivative represented by general formula (1): wherein R1 to R16 are each independently selected from a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heterocyclic group; and at least one of R1 to R8 and R10 to R15 is selected from a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heterocyclic group.

Abstract: Polyionic liquid salts are provided comprising polycationic or polyanionic molecules. Further provided are solvents comprising one or more polyionic liquid salts, and the use of such polyionic liquid salts as stationary phases in gas chromatography, and as a reagent in electrospray ionization-mass spectrometry (ESI-MS).

Abstract: A radioisotope labeled reagent includes a compound having the general formula (I), L-(aCbH2)naC5bH3??(I) where a in each occurrence independently is a carbon mass number between 11 and 14 inclusive, b in each occurrence independently is a hydrogen mass number between 1 and 3 inclusive, such that a in each occurrence is not 12 simultaneously with b in each occurrence being 1; L is a leaving group R1SO2—O—, R1—S—, 12C1H3(12C1H2)n—S—R1C(O)O—, NC—, (R1)3P—, XMg— and Li—, where n is an integer between 0 and 3 inclusive, where X is chloro, bromo or iodine, where R1 is H, aryl, a substituent containing aryl, C1-C20 alkyl, a substituent containing C1-C20 alkyl, C2-C20 alkenyl, a substituent containing C2-C20 alkenyl, C2-C20 alkynyl, and a substitute containing C2-C20 alkynyl with the proviso that when n is 0, a is 13 and b is 2 and R1 in R1—S is not aryl.

Abstract: A composition includes an inorganic particle core and an initiator molecule chemically bonded thereto. The particle core is formed of a material having a dielectric constant of about fifteen or more. The initiator molecule includes a chain having about twenty or fewer carbon atoms and a phosphorous atom chemically bonded to an end of the chain. An alkyl derivative of an aryl moiety terminates another end of the chain.

Abstract: The present invention provides P-chiral compounds of general formulae (II) and (III): in formula (II) at least one of R21, R25, R26 and R30 is independently selected from CM alkyl, CF3, C1-4 alkoxy, phenyl and benzyloxy and the remaining substituents selected from R21, R25, R26 and R30 are hydrogen; at least one of R22, R24, R27 and R29 are independently selected from C1-14 alkyl, CF3, C1-14 alkoxy, phenyl and benzyloxy and the remaining substituents selected, from R22, R24, R27 and R29 are hydrogen; and R23 and R28 are independently selected from hydrogen, CM alkyl, CF3, C1-14 alkoxy, phenyl and benzyloxy; in formula (III) at least one of R21, R25, R26 and R30 is independently selected from phenyl and benzyloxy and the remaining substituents selected from R21, R25, R?26 and R30 are hydrogen; and R22, R?23 R24, R27, R28 and R29 are independently selected from hydrogen, C1-14 alkyl, CF3, C1-14 alkoxy, phenyl and benzyloxy.

Abstract: A production method of a compound represented by the formula wherein R1a, R1b, R1c, R1d, R1e, R1f, R2a, R2b, R2c, R2d, R2e and R2f are the same or different and each is a hydrogen atom and the like, and R3, R4, R5, R6, R7, R8, R9 and R10 are the same or different and each is a hydrogen atom and the like, or a salt thereof, which comprises reacting a compound represented by the formula wherein X is a leaving group and other symbols are as defined above, or a salt thereof, with a phosphine-borane complex represented by the formula wherein the symbols are as defined above, or a salt thereof, in a solvent in the presence of an amine and a nickel catalyst, is provided.

Abstract: In one aspect, the present invention provides a contrast enhancement agent comprising an iron chelate having structure I and salts thereof wherein R1 is independently at each occurrence a hydroxy group, a C1-C3 hydroxyalkyl group, or a C1-C3 alkyl group, and b is 0-4; R2-R7 are independently at each occurrence hydrogen, a C1-C3 hydroxyalkyl group, or a C1-C3 alkyl group, with the proviso that at least one of R1-R7 is a hydroxy group or a C1-C3 hydroxyalkyl group; and wherein Q is one or more charge balancing counterions. Also provided are a metal chelating ligand having structure IX and medical formulations comprising the contrast enhancement agent I.

Abstract: A method for producing a phenylphosphonic acid metal salt, including reacting a phenylphosphonic acid compound (a) with a metal salt, metal oxide or metal hydroxide (b) that is present in an amount beyond the equivalent; a phenylphosphonic acid metal salt composition comprising a phenylphosphonic acid metal salt and surplus metal salt, surplus metal oxide or surplus metal hydroxide produced by the method; and a thermoplastic resin composition comprising the phenylphosphonic acid metal salt composition.

Abstract: The present invention provides a process for efficiently producing an alkylated aromatic compound in good yield, by a cross-coupling reaction between an alkyl halide and an aromatic magnesium reagent. A process for producing an aromatic compound represented by Formula (1): R—Ar???(1) wherein R is a hydrocarbon group, and Ar? is an aryl group; the process comprising: reacting a compound represented by Formula (2): R—X??(2) wherein X is a halogen atom, and R is as defined above, with a magnesium reagent represented by Formula (3): Ar?—MgY??(3) wherein Y is a halogen atom, and Ar? is as defined above, in the presence of a catalyst for cross-coupling reactions comprising an iron compound and a bisphosphine compound represented by Formula (4): wherein Q is a divalent group derived from an aromatic ring by removing two hydrogen (H) atoms on adjacent carbon atoms; and each Ar is independently an aryl group.

Abstract: A novel bidentate catalytic ligand of general formula (I) is described. R represents a hydrocarbyl aromatic structure having at least one aromatic ring to which Q1 and Q2 are each linked, via the respective linking group, if present, on available adjacent atoms of the at least one aromatic ring. The groups X3 and X4 represent radicals joined via tertiary carbon atoms to the respective atom Q1 and the groups X1 and X2 represent radicals joined via primary, or substituted aromatic ring carbon atom(s) to the respective atom Q2. A and B represent an optional lower alkylene linking group. Q1 and Q2 each represent phosphorus, arsenic or antimony. A process for the carbonylation of ethylenically unsaturated compounds comprising reacting the compound with carbon monoxide in the presence of a source of hydroxyl groups, optionally, a source of anions and catalyst system obtainable by combining a metal of Group 8, 9 or 10 or a compound thereof and the bidentate ligand of general formula (I) is also described.

Abstract: Compounds of the formula (I), in the form of mixtures comprising predominantly one diastereomer or in the form of pure diastereomers, Z1-Q-P*R0R1 (I) in which Z1 is a C-bonded, secondary phosphine group —P(R)2; in which R is in each case independently hydrocarbon radicals or heterohydrocarbon radicals, or Z1 is the —P*R0R1 group; Q is a bivalent, achiral, aromatic base skeleton, a bivalent, achiral ferrocene base skeleton, an optionally substituted bivalent cycloalkane or heterocycloalkane skeleton, or a C1-C4-alkylene skeleton, and in which base skeletons a secondary phosphine group Z1 is bonded directly to a carbon atom, or, in the case of cyclic base skeletons, directly to a carbon atom or via a C1-C4-alkylene group, and in which base skeletons a P-chiral group —P*R0R1 is bonded directly to a carbon atom, or, in the case of cyclic base skeletons, directly to a carbon atom or via a C1-C4-alkylene group to a carbon atom such that the phosphorus atoms are linked via 1 to 7 atoms of a carbon chain optionally i

Abstract: The present invention features a chemoselective ligation reaction that can be carried out under physiological conditions. In general, the invention involves condensation of a specifically engineered phosphine, which can provide for formation of an amide bond between the two reactive partners resulting in a final product comprising a phosphine moiety, or which can be engineered to comprise a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine byproduct and producing a native amide bond in the final product. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).

Abstract: Methods and compositions involving a class of boron-protected phenylphosphine agents having increased cell permeability and having improved chemical stability for treating or for preventing neuronal cell death-related diseases or conditions in a human or a non-human animal.

Abstract: The present invention features a chemoselective ligation reaction that can be carried out under physiological conditions. In general, the invention involves condensation of a specifically engineered phosphine, which can provide for formation of an amide bond between the two reactive partners resulting in a final product comprising a phosphine moiety, or which can be engineered to comprise a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine byproduct and producing a native amide bond in the final product. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).

Abstract: The invention provides a transition metal complex of formula (3) below: wherein R1, R2, R3, R4, R5, R6, R7 and R8 are the same or different and each independently represents a hydrogen atom, a halogen atom or a substituted or unsubstituted alkyl group having 1 to 10 carbon atom(s); R5 represents a hydrogen atom, a fluorine atom or a substituted or unsubstituted alkyl group having 1 to 10 carbon atom(s); X1 represents a hydrogen atom, a halogen atom or a substituted or unsubstituted alkyl group having 1 to 10 carbon atom(s); L represents a balancing counter ion or neutral ligand similar to X1 that is bonding or coordinating to metal M; and q represents an integer of 0 or 1, and G20 represents any one of G21 to G26 below: where A1 represents an element of Group 15 of the periodic table, wherein A1 in G23 represents an anion of an element of Group 15 of the periodic table, and A1 in G21 represents a nitrogen atom; R9, R14, R12, R13, R19, R20, R10, R11, R15, R16, R17, R18, R19, R20, R21 and R22 ea

Abstract: Disclosed is a process for producing a phosphine derivative from a phosphine oxide derivative, which comprises the following steps: (I) mixing a phosphine oxide derivative represented by formula (1) with a chlorinating agent in a polar organic solvent to cause the reaction between these components; and (II-1) adding a salt of a metal having an ionization tendency equal to or lower than that of aluminum to the reaction mixture and carrying out the reductive reaction in the presence of aluminum or (II-2) subjecting the reaction mixture to electrolytic reduction, thereby producing a phosphine derivative represented by formula (2). ArnR3-nP?O (1) ArnR3-nP (2) In formulae (1) and (2), Ar represents an aryl group such as a phenyl group, a phenyl group having a substituent, a heteroaromatic ring group, and a heteroaromatic ring group having a substituent; R represents an aliphatic hydrocarbon group or an aliphatic hydrocarbon group having a substituent; and n represents an integer of 0 to 3.

Abstract: A compound comprising a sulfonated dihydrocarbyl(arylalkyl)phosphine of formula R1R2PR3—(SO3M)n, wherein the R1 and R2 are selected individually from alkyl, aralkyl, and alicyclic groups, and R3 is a divalent or polyvalent arylalkylene radical such that the alkyl moiety is bonded to the phosphorus atom and the aryl moiety is bonded to the alkyl and is also substituted with one or more sulfonate groups; M is a monovalent cation, and n ranges from 1 to 3. The compound is useful as a ligand in transition metal-ligand complex catalysts that are capable of catalyzing the hydroformylation of an olefinically-unsaturated compound with carbon monoxide and hydrogen to form one or more corresponding aldehyde products. The ligand is incapable of alkyl-aryl exchange, thereby leading to reduced ligand usage and improved ligand and transition metal, e.g., rhodium, recovery and recycling.

Abstract: A process for preparing Erianin (Dihydro Combretastation A-4), wherein 3,4,5-trimethoxy benzaldehyde is converted to phosphonium salt or phosphonate ester or the likes thereof, then reacted with isovanillin (3-hydroxyl-4-methoxyl benzaldehyde) including a protected hydroxyl in the 3-position, followed by hydrogenation and deprotection.

Abstract: It is an object of the present invention to provide a novel phosphine compound capable of forming a metal complex useful as a catalyst for various asymmetric synthesis reactions, a production method thereof, and a metal complex comprising the aforementioned compound as a ligand. A 2,2?-bis(dialkylphosphino)biphenyl compound represented by the formula (A-1). A compound represented by the formula (1) is appropriate as a catalyst for an asymmetric synthesis reaction. The biphenyl compound represented by the formula (A-1) can be obtained by subjecting a compound represented by the formula (A-2) to a coupling reaction to obtain an intermediate represented by the formula (A-3), and then subjecting the intermediate to a deboranation reaction. In the formula (A-1), R1 and R2 each independently represent a C1-C10 alkyl group, R3 represents a monovalent substituent, and n represents an integer of 0 to 4.

Abstract: The invention relates to the use of polycyclic aromatic hydrocarbons (PAHs) such as naphthalene and its alkyl, aryl, or heteroatom substituted analogs, that act as catalysts in the presence of an alkali metal (Li, K, Na) for the reduction of electron-deficient and electron-rich triaryl phosphines to their corresponding alkali metal diaryl phosphide salts. The process is also useful for the catalysis of triaryl phosphine chalcogen adducts such as the sulfides, oxides, and selenides, diaryl(halo)phosphines, triaryl phosphine-borane adducts, and tetra-aryl bis(phosphines) that can also be reduced to their corresponding alkali metal diaryl phosphide salts. The invention also relates to small molecule PAHs and polymer tethered PAHs naphthenics.

Abstract: A method for producing a norbornene derivative wherein, in the presence of palladium and at least one selected from phosphorus compounds represented by the following General Formulae (1) and (2): [in Formula (1), R1, R2, R3 and R4 each independently represent a hydrogen atom or the like, and R5 and R6 each independently represent a branched chain saturated hydrocarbon group having 3 to 10 carbon atoms or the like], and [in Formula (2), R7 represents a branched chain saturated hydrocarbon group having 3 to 10 carbon atoms], a norbornadiene derivative represented by the following General Formula (3): [in Formula (3), R8, R9, R10, R11 and R12 each independently represent a hydrogen atom or the like, l represents an integer of 0 or 1, m represents an integer of 0 or 1, and n represents an integer of 0 or 1], and a bromine compound represented by the following General Formula (4): [Chemical Formula 4] Br—Z—R13??(4) [in Formula (4), Z represents a phenylene group or the like, and R13

Abstract: Reactions of Group 16 elements involving the addition of atoms such as sulfur, selenium or tellurium to organic or inorganic molecules comprising use of an ionic liquid as a reaction medium.

Abstract: The present invention provides P-chiral compounds of general formulae (II) and (III): in formula (II) at least one of R21, R25, R26 and R30 is independently selected from CM alkyl, CF3, C1-4 alkoxy, phenyl and benzyloxy and the remaining substituents selected from R21, R25, R26 and R30 are hydrogen; at least one of R22, R24, R27 and R29 are independently selected from C1-14 alkyl, CF3, C1-14 alkoxy, phenyl and benzyloxy and the remaining substituents selected, from R22, R24, R27 and R29 are hydrogen; and R23 and R28 are independently selected from hydrogen, CM alkyl, CF3, C1-14 alkoxy, phenyl and benzyloxy; in formula (III) at least one of R21, R25, R26 and R30 is independently selected from phenyl and benzyloxy and the remaining substituents selected from R21, R25, R—26 and R30 are hydrogen; and R22, R—23 R24, R27, R28 and R29 are independently selected from hydrogen, C1-14 alkyl, CF3, C1-14 alkoxy, phenyl and benzyloxy.

Abstract: The present invention relates to a method for preparing phosphine butadiene-type ligands, and their use, particularly as catalytic metal ligands used in the reactions leading to the formation of carbon-carbon and carbon-heteroatom bonds.

Abstract: Phosphine triazole ligand compounds, prepared through click chemistry, complex with transition metals to form transition metal-phosphine triazole ligand complexes. These complexes are useful catalysts in coupling reactions such as Suzuki-Miyaura coupling, Stille coupling, Negishi coupling, Sonagashira coupling, carbon-heteroatom bond-forming reactions (C—O and C—N), alpha alkylation of carbonyls, Heck coupling reactions, and hydrogenation reactions.

Abstract: Described herein are novel compounds having antineoplastic and antimicrobial activity, obtained via structural modifications of resveratrol and combretastatin A-4, methods for synthesis of these compounds, and their use in pharmaceutical composition and for use in the treatment of mammals having cancer. Examples of the novel compounds are: (Z)- and (E)-3,4?,5-trimethoxystilbene (4a, 4b); (Z)- and (E)-3,5-dimethoxy-4?-hydroxystilbene (14c, 14d); (Z)- and (E)-3-hydroxy-4?,5-dimethoxystilbene (14g, 14h); (Z)- and (E)-3,5-dihydroxy-4?-methoxy-stilbene (14k, 14l); sodium resverastatin dibenzyl phosphate ((Z)-3,5-dimethoxy-4-[O-bis(benzyl)phosphoryl]-stilbene) (14m); and sodium resverastatin phosphate (14n).

Abstract: A skin agent for external use and a cosmetic agent are provided, by transdermal administration of which expected actions and effects of ubiquinone derivatives, salts thereof, ubiquinones and ubiquinols are effectively obtained. The skin agent for external use includes a ubiquinone derivative or a salt thereof as an active ingredient. The ubiquinone derivative is represented by the formula (1): wherein R1 and R2 are each a hydrogen atom or a phosphoric group, at least one of R1 and R2 is a phosphoric group, and n is an integer in the range of 1 to 9.

Abstract: The present invention relates to novel truxene and isotruxene derivatives, in particular spirotruxene and spiroisotruxene derivatives, and to the use thereof in organic electronic devices, in particular organic electroluminescent devices.

Abstract: A production method of a compound represented by the formula wherein R1a, R1b, R1c, R1d, R1e, R1f, R2a, R2b, R2c, R2d, R2e and R2f are the same or different and each is a hydrogen atom and the like, and R3, R4, R5, R6, R7, R8, R9 and R10 are the same or different and each is a hydrogen atom and the like, or a salt thereof, which comprises reacting a compound represented by the formula wherein X is a leaving group and other symbols are as defined above, or a salt thereof, with a phosphine-borane complex represented by the formula wherein the symbols are as defined above, or a salt thereof, in a solvent in the presence of an amine and a nickel catalyst, is provided.

Abstract: Processes for recovering at least one triarylphosphine from a Group VIII metal catalyst triarylphosphine complex mixture are provided. The processes are particularly useful for recovering the triarylphosphine from spent Group VIII metal catalyst complex mixtures. The processes include the steps of (i) forming a distillate from a Group VIII catalyst complex mixture containing a Group VIII metal catalyst complex, a triarylphosphine, and a light ends component wherein the distillate contains at least a portion of the triarylphosphine as a vapor and at least a portion of the light ends component as a vapor; (ii) cooling the distillate to a temperature below the boiling point of the light ends component to form a condensate; (iii) crystallizing at least a portion of the triarylphosphine using the light ends component as a crystallizing liquid; and (v) recovering the crystallized triarylphosphine from the condensate.

Abstract: A phosphine compound represented by general formula (1) wherein R? and R? independently are selected from alkyl, cycloalkyl and 2-furyl radicals, or R? and R? are joined together to form with the phosphorous atom a carbon-phosphorous monocycle including at least 3 carbon atoms or a carbon-phosphorous bicycle; the alkyl radicals, cycloalkyl radicals, and carbon-phosphorous monocycle being unsubstituted or substituted by at least one radical selected from the group of alkyl, cycloalkyl, aryl, alkoxy, and aryloxy radicals; Cps is a partially substituted or completely substituted cyclopentadien-1-yl group, including substitutions resulting in a fused ring system, and wherein a substitution at the 1-position of the cyclopentadien-1-yl group is mandatory when the cyclopentadien-1-yl group is not part of a fused ring system or is part of an indenyl group. These phosphines can be used as ligands in catalytic reactions.

Abstract: 1,1?-Biphenyl-2,2?-diphosphines having at least one amine substituent in the para position relative to the phosphine group and having the formulae are ligands for metal complexes which serve as catalysts for asymmetric addition reactions of prochiral organic compounds and whose catalytic properties can be tailored specifically to particular substrates by substitution of the amine group.

Abstract: (Pentafluorophenyl) Group 11 and 12 metal compounds and processes for preparing (pentafluorophenyl) Group 11 and 12 metal compounds are disclosed. Also, disclosed are processes for preparing (pentafluorophenyl) Group 13 or 15 metal compounds useful as Lewis acids. Compositions with low levels of base impurities and products produced by the novel processes are also disclosed.

Abstract: The present application describes deuterium-enriched fospropofol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.

Abstract: Organic ligands that contain at least one aryl group are immobilized on a solid support. The organic ligands are of the type used to form a catalyst complex suitable for carrying out a catalytic reaction, preferably an asymmetric reaction. To immobilize the organic ligands, a tethering group is bonded to the ligand using, for example, a Friedel-Crafts acylation or alkylation reaction. The immobilization of the organic ligand can be carried out using a single reaction with the organic ligand.

Abstract: This invention provides a method for generating secondary phosphines from secondary phosphine oxides in the presence of a reducing agent, such as diisobutylaluminum hydride (DIBAL-H), triisobutyldialuminoxane, triisobutylaluminum, tetraisobutyldialuminoxane, or another reducing agent comprising: (i) an R1R2AlH moiety, wherein R1 and R2 are each an alkyl species or oxygen, and wherein at least one of R1 or R2 comprises at least 2 carbon atoms, or (ii) an R1R2R3Al moiety, wherein R1, R2, and R3 are not hydrogen, and wherein at least one of R1, R2, and R3 is an alkyl species comprising a ?-hydrogen, not including triethylaluminum. Preferred reducing agents for the present invention include: diisobutylaluminum hydride, triisobutyldialiuminoxane, triisobutylaluminum, tetraisobutyldialuminoxane, and combinations thereof.

Abstract: The present invention relates to mixed calcium/sodium salt of inositol tripyrophosphate, methods of preparing and methods of use. The mixed calcium/sodium salt may be a monocalcium tetrasodium salt of inositol tripyrophosphate. Methods of use include administering the above salts in an effective amount to treat diseases caused by hypoxia or other conditions associated with inadequate function of the lungs or circulatory system, such as various types of cancer and Alzheimer's disease.

Abstract: The present invention relates to the improvement of organic electroluminescent devices, in particular blue-emitting devices, by using compounds of the formula (1) as host materials in the emitting layer.

Abstract: A novel transition metal complex, preferably a ruthenium-phosphine complex or rhodium-phosphine complex, which is effectively usable in various asymmetric syntheses and, in particular, is more effectively usable in the asymmetric hydrogenation of various ketones; and a novel process for producing an optically active alcohol with the complex. The novel transition metal complex includes a ligand obtained by introducing a diarylphosphino group into each of the 2- and 2?-positions of diphenyl ether, benzophenone, benzhydrol, or the like. It preferably further includes an optically active 1,2-diphenylethylenediamine coordinated thereto. The complex preferably is a novel diphosphine-ruthenium-optically active diamine complex or diphosphine-rhodium-optically active diamine complex. The process comprises using the complex as an asymmetric hydrogenation catalyst to conduct the asymmetric hydrogenation of a ketone compound to thereby obtain an optically active alcohol in a high optical purity and a high yield.

Abstract: The present invention relates to a method for the preparation of C2-symmetric 1,4-diols of the formula IVA or IVB, wherein ring A, R1 and R2 have the meanings given in the specification, that makes use of the metallation of pure enantiomers of ?-(aryl or heteroaryl)-?-substituted alkanol compounds or the use of said alkanol compounds in the preparation of said mmetric 1,4-diols; novel C2-symmetric 1,4-diols in enantiomerically pure form; and methods of use or their use in the synthesis of chiral ligands which find use to produce catalysts for a variety of asymmetric transformations such as hydrogenations.

Abstract: The present invention relates to a new, selective process for the preparation of mono- and bisacylphosphanes of formula (I) n and m are each independently of the other 1 or 2; R1, if n=1, is e.g. phenyl R1, if n=2, is e.g. C1-C18alkylene or phenylene; R2 is e. g. C1-C18alkyl, phenyl or substituted phenyl; R3 is e. g. C1-C18alkyl, by (1) reacting a phosphorous halide of formula IIa or a phosphorous halide oxide of formula (IIb) or a phosphorous halide sulfide of formula (IIc) with an alkali metal in a solvent in the presence of a proton source; (2) subsequent reaction with m acid halides of formula (III) An oxidation step may follow to obtain mono- and bisacylphosphane oxides or mono- and bisacylphosphane sulfides.

Abstract: Compounds of formula II wherein each R1 and R2 is independently selected from H and —P(O)(R3)(R4), provided that at least one of R1 and R2 is —P(O)(R3)(R4); each R3 and R4 is independently selected from the group consisting of H, —OH, C1-C6 alkyl and C1-C6 alkoxy; or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising a compound of formula II, and methods of administering such compounds and compositions.

Abstract: Polyionic liquid salts are provided comprising polycationic or polyanionic molecules. Further provided are solvents comprising one or more polyionic liquid salts, and the use of such polyionic liquid salts as stationary phases in gas chromatography, and as a reagent in electrospray ionization-mass spectrometry (ESI-MS).

Abstract: A method of making an aryl phosphine is provided. The method comprises reacting an organophosphine of general formula (1): HPXY with a substituted aryl compound in the presence of a catalyst, a base, a ligand and an iodine containing co-catalyst. In formula (1) X and Y can be the same or different and are cycloalkyl; substituted alkyl; primary, secondary and tertiary alkyl; and heterocyclic moieties; and one of X and Y can optionally be hydrogen.

Abstract: Non-C2-symmetric bisphospholane ligands and methods for their preparation are described. Use of metal/non-C2-symmetric bisphospholane complexes to catalyze asymmetric transformation reactions to provide high enantiomeric excesses of formed compounds is also described.

Abstract: A process for preparing a functionalized polymerization initiator, the process comprising combining a functionalized styryl compound and an organolithium compound.